-
rabindra.tharu.np@gmail.com
·
Large-scale deep proteomic analysis in Alzheimer’s disease brain regions across race and ethnicity
INTRODUCTION Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease, yet our comprehension predominantly relies on studies within non-Hispanic White (NHW) populations. Here we provide an extensive survey of the proteomic landscape of AD across diverse racial/ethnic groups. METHODS Two cortical regions, from multiple centers, were harmonized by uniform neuropathological diagnosis. Among 998 unique donors,…
-
rabindra.tharu.np@gmail.com
·
Association of common and rare variants with Alzheimer’s disease in more than 13,000 diverse individuals with whole-genome sequencing from the Alzheimer’s Disease Sequencing Project
INTRODUCTION Alzheimer’s disease (AD) is a common disorder of the elderly that is both highly heritable and genetically heterogeneous. METHODS We investigated the association of AD with both common variants and aggregates of rare coding and non-coding variants in 13,371 individuals of diverse ancestry with whole genome sequencing (WGS) data. RESULTS Pooled-population analyses of all…
-
rabindra.tharu.np@gmail.com
·
Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology
INTRODUCTION Blood tests have the potential to improve the accuracy of Alzheimer’s disease (AD) clinical diagnosis, which will enable greater access to AD-specific treatments. This study compared leading commercial blood tests for amyloid pathology and other AD-related outcomes. METHODS Plasma samples from the Alzheimer’s Disease Neuroimaging Initiative were assayed with AD blood tests from C2N…
-
rabindra.tharu.np@gmail.com
·
Modifiable dementia risk factors associated with objective and subjective cognition
INTRODUCTION Early detection of both objective and subjective cognitive impairment is important. Subjective complaints in healthy individuals can precede objective deficits. However, the differential associations of objective and subjective cognition with modifiable dementia risk factors are unclear. METHODS We gathered a large cross-sectional sample (N = 3327, age 18 to 84) via a smartphone app and quantified…
-
rabindra.tharu.np@gmail.com
·
Digital cognitive assessments as low-burden markers for predicting future cognitive decline and tau accumulation across the Alzheimer’s spectrum
BACKGROUND Digital cognitive assessments, particularly those that can be done at home, present as low-burden biomarkers for participants and patients alike, but their effectiveness in the diagnosis of Alzheimer’s disease (AD) or predicting its trajectory is still unclear. Here, we assessed what utility or added value these digital cognitive assessments provide for identifying those at…
-
rabindra.tharu.np@gmail.com
·
Cognitive modeling of the Mnemonic Similarity Task as a digital biomarker for Alzheimer’s disease
BACKGROUND The Mnemonic Similarity Task (MST) is a popular memory task designed to assess hippocampal integrity. We assessed whether analyzing MST performance using a multinomial processing tree (MPT) cognitive model could detect individuals with elevated Alzheimer’s disease (AD) biomarker status prior to cognitive decline. METHOD We analyzed MST data from >200 individuals (young, cognitively healthy older…
-
rabindra.tharu.np@gmail.com
·
Missense and loss-of-function variants at GWAS loci in familial Alzheimer’s disease
BACKGROUND Few rare variants have been identified in genetic loci from genome-wide association studies (GWAS) of Alzheimer’s disease (AD), limiting understanding of mechanisms, risk assessment, and genetic counseling. METHODS Using genome sequencing data from 197 families in the National Institute on Aging Alzheimer’s Disease Family Based Study and 214 Caribbean Hispanic families, we searched for…
-
rabindra.tharu.np@gmail.com
·
The ADNI4 Digital Study: A novel approach to recruitment, screening, and assessment of participants for AD clinical research
INTRODUCTION We evaluated preliminary feasibility of a digital, culturally-informed approach to recruit and screen participants for the Alzheimer’s Disease Neuroimaging Initiative (ADNI4). METHODS Participants were recruited using digital advertising and completed digital surveys (e.g., demographics, medical exclusion criteria, 12-item Everyday Cognition Scale [ECog-12]), Novoic Storyteller speech-based cognitive test). Completion rates and assessment performance were compared…
-
rabindra.tharu.np@gmail.com
·
Bridging the gap: Multi-omics profiling of brain tissue in Alzheimer’s disease and older controls in multi-ethnic populations
INTRODUCTION Multi-omics studies in Alzheimer’s disease (AD) revealed many potential disease pathways and therapeutic targets. Despite their promise of precision medicine, these studies lacked Black Americans (BA) and Latin Americans (LA), who are disproportionately affected by AD. METHODS To bridge this gap, Accelerating Medicines Partnership in Alzheimer’s Disease (AMP-AD) expanded brain multi-omics profiling to multi-ethnic…
-
rabindra.tharu.np@gmail.com
·
Standardized statistical framework for comparison of biomarkers: Techniques from ADNI
INTRODUCTION Well-chosen biomarkers have the potential to increase the efficiency of clinical trials and drug discovery and should show good precision as well as clinical validity. METHODS We suggest measures that operationalize these criteria and describe a general approach that can be used for inference-based comparisons of biomarker performance. The methods are applied to measures…
